Abstract
Congestive Heart Failure (CHF) is an emerging epidemic. Within one generation, the medical community has learned much of CHF syndromes. It has two distinct mechanisms, systolic and diastolic abnormalities, to account for the common CHF presentation. It is complex as it challenges the available health care services, resource, and funding models in providing an equitable service across the health continuum. Despite the improvement in many cardiovascular diseases, some CHF outcomes like readmissions and costs have increased. The reinvigoration of evidence- based medicine, the development of health services models of care, and standardisation of disease processes with taxonomies have also occurred within the same time span. These processes, however, need to be linked with health policy as presented in white papers. In this paper, we explore achieving optimal CHF guideline-recommended outcomes as the science approaches realworld translation.
Keywords: Congestive heart failure, cost-efficacy, health services, taxonomy, white-papers, health systems.
Current Cardiology Reviews
Title:Part 1: The Wider Considerations in Translating Heart Failure Guidelines
Volume: 17 Issue: 5
Author(s): Pupalan Iyngkaran*, Andrew Wilson, James Wong, David Prior, David Kaye, David L Hare, Peter Bergin and Michael Jelinem
Affiliation:
- Department of Cardiology, St. Vincent's Hospital, Melbourne, Victoria,Australia
Keywords: Congestive heart failure, cost-efficacy, health services, taxonomy, white-papers, health systems.
Abstract: Congestive Heart Failure (CHF) is an emerging epidemic. Within one generation, the medical community has learned much of CHF syndromes. It has two distinct mechanisms, systolic and diastolic abnormalities, to account for the common CHF presentation. It is complex as it challenges the available health care services, resource, and funding models in providing an equitable service across the health continuum. Despite the improvement in many cardiovascular diseases, some CHF outcomes like readmissions and costs have increased. The reinvigoration of evidence- based medicine, the development of health services models of care, and standardisation of disease processes with taxonomies have also occurred within the same time span. These processes, however, need to be linked with health policy as presented in white papers. In this paper, we explore achieving optimal CHF guideline-recommended outcomes as the science approaches realworld translation.
Export Options
About this article
Cite this article as:
Iyngkaran Pupalan*, Wilson Andrew , Wong James , Prior David , Kaye David , Hare L David, Bergin Peter and Jelinem Michael, Part 1: The Wider Considerations in Translating Heart Failure Guidelines, Current Cardiology Reviews 2021; 17(5) : e160721190003 . https://dx.doi.org/10.2174/1573403X16666210108104945
DOI https://dx.doi.org/10.2174/1573403X16666210108104945 |
Print ISSN 1573-403X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6557 |

- Author Guidelines
- Editorial Policies
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Allegations from Whistleblowers
- Publishing Ethics and Rectitude
- Increase Visibility Of Your Article
- Archiving Policies
- Reviewer Guidelines
- Guest Editor Guidelines
- Board Recruitment Workflow
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Combination of Statin Plus Renin Angiotensin System Inhibition for the Prevention or the Treatment of Atherosclerotic Cardiovascular Disease
Current Pharmaceutical Design Angiotensin II, Cell Proliferation and Angiogenesis Regulator: Biologic and Therapeutic Implications in Cancer
Current Vascular Pharmacology Resveratrol and Its Analogues: Promising Antitumor Agents
Anti-Cancer Agents in Medicinal Chemistry The Etiology of Hypertension in the Metabolic Syndrome Part Three: The Regulation and Dysregulation of Blood Pressure
Current Vascular Pharmacology Endoplasmic Reticulum Stress Inhibition Enhances Liver Tolerance to Ischemia/Reperfusion
Current Medicinal Chemistry Design and Development of Solid Dispersion of Valsartan by a Lyophilization Technique: A 3<sup>2</sup> Factorial Design Approach
Micro and Nanosystems Developments in Imaging Technologies Related to Hypertensive Cardiovascular Diseases
Current Pharmaceutical Design Atherogenesis in Renal Patients: A Model of Vascular Disease?
Current Vascular Pharmacology Pancreatic Cancer: Promises and Failures of Target Therapies
Reviews on Recent Clinical Trials Potential Interactions between miRNAs and Hypoxia: A New Layer in Cancer Hypoxia
Anti-Cancer Agents in Medicinal Chemistry Role of Oxidative Stress and Mitochondrial Dysfunction in Skeletal Muscle in Type 2 Diabetic Patients
Current Pharmaceutical Design Structural Alterations of the Retinal Microcirculation in the “Prehypertensive” High- Normal Blood Pressure State
Current Pharmaceutical Design Incretins Yesterday, Pleiotropic Gastrointestinal Hormones Today:Glucagon-Like Peptide-1 (GLP-1) and Glucose-ependent Insulinotropic Polypeptide (GIP)
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Retroviral Vector-mediated Gene Therapy for Metabolic Diseases: An Update
Current Pharmaceutical Design TRPM6 and TRPM7: A Mul-TRP-PLIK-Cation of Channel Functions
Current Pharmaceutical Biotechnology Hepatocellular Carcinoma Targeting and Pharmacodynamics of Paclitaxel Nanoliposomes Modified by Glycyrrhetinic Acid and Ferric Tetroxide
Current Topics in Medicinal Chemistry Glibenclamide Action on Myocardial Function and Arrhythmia Incidence in the Healthy and Diabetic Heart
Cardiovascular & Hematological Agents in Medicinal Chemistry Immunoregulatory and Effector Activities of Nitric Oxide and Reactive Nitrogen Species in Cancer
Current Medicinal Chemistry Calcium Ion – The Key Player in Cerebral Ischemia
Current Medicinal Chemistry Role of Vascular Progenitor Cells in Cardiovascular Disease
Current Pharmaceutical Design